Center-Authored Papers

Filters: Author is Steensma, David P  [Clear All Filters]
Journal Article
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X et al..  2016.  Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.. BMC cancer. 16:652. Abstract
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ et al..  2013.  Myeloid growth factors.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(10):1266-90. Abstract
Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ et al..  2011.  Myeloid growth factors.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(8):914-32.
Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F.  2014.  Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.. Blood. 123(3):451-2.
Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ et al..  2016.  Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).. Haematologica. Abstract
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U et al..  2016.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.. The Lancet. Oncology. Abstract